Prediction of Survival Outcome in Lower-Grade Glioma Using a Prognostic Signature with 33 Immune-Related Gene Pairs
Shaohua Chen,Yongchu Sun,Xiaodong Zhu,Zengnan Mo
DOI: https://doi.org/10.2147/IJGM.S338135
IF: 2.145
2021-11-14
International Journal of General Medicine
Abstract:Shaohua Chen, 1, 2, &ast Yongchu Sun, 3, 4, &ast Xiaodong Zhu, 3– 5 Zengnan Mo 1, 2 1 Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China; 2 Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, People's Republic of China; 3 Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, People's Republic of China; 4 Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Guangxi Medical University, Nanning, People's Republic of China; 5 Department of Oncology, Affiliated Wuming, Hospital of Guangxi Medical University, Nanning, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaodong Zhu Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, No. 71 He Di Road, Nanning, 530021, People's Republic of China Email Zengnan Mo Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning, 530021, People's Republic of China Email Background: Lower-grade glioma (LGG) is one of the prevalent malignancies threatening human health, with considerable intrinsic heterogeneities in their biological behavior. Previous studies have revealed that the immune component is a key factor influencing the formation and development of malignancies. In this study, we aim to use a novel approach to develop a prognostic signature of immune-related gene pairs (IRGPs) to determine the survival outcome of patients with LGG. Methods: Transcriptomic profiles and clinical data for LGG were obtained from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases, and used as training and validation data sets, respectively. IRGPs influencing the overall survival (OS) of patients with LGG in the training data set were screened by performing univariate Cox regression analysis. Next, a prognostic IRGPs signature was constructed using least absolute shrinkage and selection operator (LASSO) regression. Finally, we cross-validated the two databases to verify the stability of the prognostic signature. Results: A total of 33 IRGPs influencing prognosis of LGG in the training data set were included in the prognostic signature. Patients with high risk scores (RSs) in the training and validation data sets had a poorer OS than those with low RSs. Moreover, significant differences were observed in tumor-infiltrating immune cells (TICs) between high- and low-RS groups. Functional enrichment analyses results revealed that genes in the high-RS group were enriched in the immune-related activities and developmental processes. Conclusion: The prognostic signature containing 33 IRGPs has a significant correlation with OS and relative levels of immune cells associated with LGG. The results of the present study provide new insights into the prediction of survival outcome and therapeutic response of LGG. Keywords: lower-grade glioma, immune-related gene pairs, tumor-infiltrating immune cells, prognostic signature Gliomas are the most prevalent types of primary malignant tumors in the central nervous system. 1 Based on the histopathological features outlined by the World Health Organization (WHO), grade II and III gliomas are defined as lower-grade gliomas (LGGs), 2 which include astrocytomas, oligodendrogliomas, and oligoastrocytomas. 3 Currently, the standard care for LGG comprises surgical resection combined with postoperative radiotherapy and chemotherapy. LGG exhibits considerable intrinsic heterogeneity in biological behavior, with overall survival (OS) ranging from 1 to 15 years. 4 Nevertheless, there are some patients who develop drug-resistant high-grade gliomas, resulting in adverse long-term outcomes. Despite advances in the diagnosis and treatment modalities of LGG in recent years, the prognosis of patients with LGG has not improved substantially over the last few decades. 4,5 Therefore, identification of novel targets or biomarkers to facilitate early diagnosis and treatment response of LGG is imperative. Risk classification of glioma has been frequently applied in clinical decision-making, and WHO established specific molecular markers for brain tumor classification in 2016, such as chromosome 1p and 19q (chr1p/19q) co-deletions, isocitrate dehydrogenase, and histone H3K27M mutations. 6 This classification is superior to the previous histopathological classification. However, the widespread clinical dissemination of su -Abstract Truncated-
medicine, general & internal